Table 8.

Marketed patents/technologies [157].

Marketed Patent/Technology	Polysaccharide-Based Drug Delivery Systems	Reference
Water insoluble polymer: indigestible water-soluble polysaccharide film coatings for colon targeting. Patent no. US9107819B2. 18 August 2015	This formulation contains prednisolone sodium metasulfobenzoate, which is surrounded by a coating made up of glassy amylose, ethyl cellulose, and dibutyl sebacate. The ratio of amylose to ethyl cellulose falls between 1:3.5 and 1:4.5, and the amylose used is derived from either corn or maize.	[158]
Hyaluronic acid modification products and drug carrier using them. Patent no. US7767806B2 3 August 2010	This product is a modified version of hyaluronic acid that includes a polymer bonded to it. The polymer can be polylactic acid, polyglycolic acid, or lactic acid–glycolic acid copolymer. This modified hyaluronic acid serves as an efficient carrier for low molecular weight drugs, providing sustained-release over a long period of time, controlling blood residence, and being well-dispersible in an aqueous solution. Moreover, it has excellent biocompatibility.	[159]
Tsiros, D. and Nugent, M.A. Compositions and methods for the treatment of angiogenesis-related diseases (2020). Patent no. WO2020219497A1 29 October 2020	Avastin, also known as Bevacizumab, is an antibody that works by binding to VEGF and preventing it from binding to VEGF receptors on endothelial cells. It is commonly used to treat cancers and other diseases that involve excessive growth of blood vessels. To enhance its anti-VEGF activity, Avastin was conjugated with either biotin or streptavidin, and biotin–heparin was utilized to bring the two molecules closer together through biotin–streptavidin binding.	[160]
Drug-coated medical devices. Patent no. CN107206129B 2 March 2021	A drug-coated balloon is designed to enhance the efficiency of drug transfer and reduce drug loss. These balloons are primarily made up of a single active pharmaceutical layer that uses small, hydrophilic molecules as carriers. Examples of these carriers include urea, sorbitol, polysorbate, micelles, oil or lipid vehicles, contrast agents, iopromide, iodophorol, resveratrol, surfactants, and sodium alginate polysaccharide. It is important to note that increasing the efficiency of drug transfer can sometimes lead to a higher amount of drug loss, and vice versa.	[161]
Medical implants with polysaccharide drug-eluting coatings Patent number: US7939096B2 10 May 2011 Publication of US7939096B2	A medical implant has a bioerodible metal section and a protective layer. The layer has a therapeutic substance and a polysaccharide matrix, cross-linked with metal cations. Upon insertion, the substance is released, and the metal dissolves to recrosslink the matrix.	[162]